Checkpoint inhibitors are a new class of drugs used by the immune system to determine whether or not to launch an immune response. By activating these checkpoints, cancers evade detection by the immune system as something that is bad for…
A lymphoma diagnosis can be challenging to cope with at any time, but the current pandemic has only increased stress, anxiety, and depression for many lymphoma patients. While at times this can all be overwhelming, there are many ways to…
The emergence of biomarking testing has provided new insights into the molecular and genetic underpinnings of many types of cancer as well as differences in an individual patient’s cancer at the molecular level. These differences, or alterations (also known as…
On December 11 and 18, 2020 the U.S. Food and Drug Administration (FDA) issued two COVID-19 vaccines, Pfzier BioNTech and Moderna, with emergency use authorization (EUA). LRF Scientific Advisory Board Member, John Leonard, MD (NewYork-Presbyterian Hospital, Weill Cornell Medicine) answered…
In May 2020, lymphoma-expert, Raghuveer Ranganthan, MD (Univerity of Southern California) hosted the Lymphoma Research Foundation’s Update on CAR T-Cell Therapy in Diffuse Large B-cell Lymphoma Webinar. Due to the interest surrounding CAR T-cell therapy to treat various types of…
During the Lymphoma Research Foundation’s Denver Ask the Doctor About Lymphoma Program, lymphoma-expert and program host, John M. Burke, MD (Rocky Mountain Cancer Center), provided the following answer to this question: How can patients access innovative drug treatments when insurance…
On July 31, 2020 the U.S. Food and Drug Administration (FDA) announced it has approved tafasitamab-cxix (MONJUVI, MorphoSys US Inc.), a CD19-directed cytolytic antibody, in combination with lenalidomide (REVLIMID) for adult patients with relapsed or refractory diffuse large B-cell lymphoma…